Stemphylium botryosum Allergy Shots: What Your Panel Result Really Means
Stemphylium botryosum is a Pleosporaceae mold so closely related to Alternaria that a positive test nearly always points to the Alternaria SCIT pathway — no species-specific RCT exists for Stemphylium SCIT. Alternaria/Stemphylium co-sensitization is documented in up to 80% of patients positive to either extract (Asero 2014). The honest clinical question is not whether Stemphylium shots exist, but whether your Pleosporaceae sensitization warrants Alternaria-based SCIT.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Stemphylium botryosumis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Stemphylium botryosum Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to stemphylium botryosum — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of stemphylium botryosum allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of stemphylium botryosum immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of stemphylium botryosum extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for stemphylium botryosum allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing stemphylium botryosum extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription stemphylium botryosum immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat stemphylium botryosum allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Stemphylium botryosum?
The biology, taxonomy, and clinical fingerprint of Stemphylium botryosum — the foundation of how SCIT targets it.
Stemphylium botryosum produces dark muriform conidia nearly identical in appearance to Alternaria, explaining their frequent co-detection in air samples.
- Scientific name
- Stemphylium botryosum (teleomorph: Pleospora tarda)
- Family
- PleosporaceaePleosporales family
- Type
- Outdoor dematiaceous mold spore
- Native to
- Temperate North America and Europe; alfalfa and grass leaf-blight pathogen
- Allergen proteins
- Stem b 4 (protein disulfide isomerase, homologue of Alt a 4)Alt a 1 homologues (Pleosporaceae-shared, not yet formally named)
- Particle size
- Dark muriform phragmospores, multi-septate
- Avoidance difficulty
- Very difficult
How Stemphylium botryosum Allergy Presents
Symptoms by body system — useful for distinguishing Stemphylium botryosum sensitivity from overlapping allergies and infections.
Respiratory
- Allergic rhinitis with nasal congestion and sneezing
- Asthma exacerbations during late-summer spore peaks
- Bronchospasm triggered by thunderstorm-related spore fragmentation
- Wheezing and chest tightness in sensitized asthmatics
Ocular
- Itchy, watery eyes during outdoor high-spore days
- Conjunctival redness and tearing
- Periorbital puffiness
Dermal
- Atopic dermatitis flares during peak mold season
- Contact urticaria in sensitized individuals after direct handling
- Non-specific skin itching during high-count periods
Systemic
- Fatigue from chronic allergen exposure during fall season
- Sleep disruption from uncontrolled rhinitis
- Reduced exercise tolerance in asthmatic patients
- Headache associated with sinus congestion
When I see a Stemphylium-positive result, I treat it as a confirmatory finding within a Pleosporaceae workup — not as a standalone diagnosis. The question I ask is whether rAlt a 1 also comes back positive, because that is what drives the SCIT decision. We do not give Stemphylium shots; we give Alternaria shots with the Kuna 2011 and Tabar 2019 evidence behind them.
When & Where Stemphylium botryosum Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: late August through September (parallel to Alternaria season)· Approximately 10-12 weeks of meaningful outdoor spore load in temperate regions
US Exposure Map
9 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Moderate
- ND:
- Moderate
- MN:
- High
- WI:
- High
- MI:
- Moderate
- NY:
- Moderate
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Moderate
- SD:
- Moderate
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- Moderate
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Moderate
- NE:
- High
- MO:
- High
- KY:
- Moderate
- WV:
- Moderate
- VA:
- Moderate
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- High
- AR:
- Low
- TN:
- Moderate
- NC:
- Low
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Stemphylium botryosum Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Stemphylium botryosum shares the Stem b 4 protein (protein disulfide isomerase) with Alternaria's Alt a 4, producing confirmed IgE cross-reactivity in inhibition studies (Olivieri 2003). This shared protein is why Stemphylium sensitization is almost inseparable from Alternaria sensitization.
Stem b 4 shares high sequence identity with Alt a 4; Alt a 1 homologues present across Pleosporaceae (Olivieri 2003)
Ulo c 1 shares 89% sequence identity with Alt a 1, overlapping with Stemphylium homologues (IUIS)
Is SCIT Right for Your Stemphylium botryosum Allergy?
Answer five questions to assess whether your Stemphylium/Pleosporaceae sensitization profile is a strong candidate for Alternaria-based SCIT.
How severe are your mold-season symptoms (late summer through fall)?
The Stemphylium botryosum SCIT Protocol
When Stemphylium botryosum sensitization is confirmed as part of a Pleosporaceae sensitization pattern, SCIT is administered as an Alternaria-based extract — no separate Stemphylium vial exists in clinical practice. The Alternaria extract carries the family-level RCT evidence (Kuna 2011, Tabar 2019).
Weekly escalating doses of non-standardized Alternaria extract. With Curex, the prescribing physician supervises the first injection from each new vial or concentration live in the Virtual Shot Room and confirms a prescribed epinephrine auto-injector on hand. Mold extracts are kept in a separate vial from pollen extracts to prevent protease degradation. Pre-injection peak flow measurement is recommended given the Pleosporaceae-asthma severity association documented by O'Hollaren 1991 NEJM.
Maintenance phase continues once the target dose is reached, typically on a schedule individualized by your allergist. Your allergist will titrate the concentration based on local reaction size and symptom response. Component testing with rAlt a 1 is used to confirm clinical response trajectory.
After 3-5 years of successful maintenance, your allergist will assess whether lasting tolerance has been achieved. Patients with severe asthma or confirmed high-titer Pleosporaceae sensitization may require extended courses beyond 5 years.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Stemphylium botryosum SCIT
No SCIT-specific RCT has been published for Stemphylium botryosum. Clinical decisions extrapolate from the Alternaria DBPC-RCT evidence base, given confirmed Stem b 4 / Alt a 4 cross-reactivity and shared Pleosporaceae family membership.
- Alternaria SCIT: Combined symptom-medication score reduction63%Kuna et al., J Allergy Clin Immunol 2011, N=111 children, 3-year DBPC-RCT
- Alternaria SCIT: Symptom reduction after 1 year (native Alt a 1)45%Tabar et al., J Allergy Clin Immunol 2019, purified native Alt a 1 DBPC-RCT
No published SCIT RCT isolates Stemphylium botryosum as the immunizing antigen. The Alternaria DBPC-RCT data (Kuna 2011: 63.5% combined score reduction; Tabar 2019: significant improvement after 1 year) provides the operative evidence framework for any Pleosporaceae SCIT decision. A board-certified allergist can determine whether your specific sensitization pattern justifies applying this evidence to your case.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Stemphylium botryosum SCIT Side Effects
Side effects of Alternaria-based mold SCIT (the practical treatment approach when Stemphylium is the presenting sensitization) include local and systemic reactions consistent with standard SCIT rates. Mold extracts carry higher protease content than pollen extracts, increasing local reaction potential.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection site swelling Wheal and erythema at injection site, peaking 15-20 minutes post-injection; typically resolves within hours | Rate 30-50% | Mild |
Large local reaction (>5 cm) More common with mold extracts due to protease content; may require dose adjustment | Rate 10-20% | Moderate |
Injection site itching Can be managed with topical antihistamine cream | Rate 20-40% | Mild |
Delayed local reaction Swelling or tenderness appearing 4-12 hours after injection | Rate 5-15% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or ocular flare Sneezing or watery eyes within 30 minutes of injection | Rate 0.5-1% | Mild |
Urticaria (hives) Generalized hives requiring antihistamine treatment; monitor for escalation | Rate 0.1-0.5% | Moderate |
Asthma exacerbation Peak flow check before each injection is recommended; do not inject if PEF <80% of personal best | Rate 0.1-0.3% | Severe |
Anaphylaxis Very rare; Curex supervises the first injection from each new vial or concentration live in the Virtual Shot Room with a prescribed epinephrine auto-injector confirmed on hand | Rate <0.01% | Severe |
Systemic reactions, when they occur, typically begin within about 30 minutes of an injection. With Curex at-home mold SCIT, the prescribing physician supervises the first injection from each new vial or concentration live in the Virtual Shot Room and confirms a prescribed epinephrine auto-injector on hand before the first injection. Patients with active asthma should have peak flow measured before each injection. Pre-seasonal timing of build-up (spring) before the late-summer Stemphylium/Alternaria peak is clinically recommended.
SCIT vs Alternatives for Stemphylium botryosum
Patients with confirmed Stemphylium/Alternaria Pleosporaceae sensitization have four main management options: Alternaria-based SCIT, at-home SLIT drops, environmental controls and avoidance, or daily antihistamines and nasal steroids.
| Criterion | At-Home SCIT (Curex, Alternaria-based)Best | SLIT drops | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | 63% combined score reduction (Kuna 2011) | Limited data; Alternaria SLIT shows improvement (Cortellini 2010) | Partial — outdoor mold avoidance is limited | Symptomatic relief; does not address sensitization |
| 5-yr cost | $3,500-$8,000 over 5 years | $500-$2,000/yr | HEPA filters $100-$500/yr | $500-$2,000/yr ongoing |
| Duration | 3-5 years | 3-5 years | Ongoing | Ongoing daily use |
| Convenience | At-home self-injection; weekly then monthly | Daily at-home drops | Lifestyle modification required | Daily pills/sprays |
| Safety | Systemic reactions <1%; Virtual Shot Room–supervised dosing + prescribed epi | Lower systemic reaction risk than SCIT | No injection risks | Drug side effects with long-term use |
| Lasting effect | Yes — tolerance may persist after completion | Evidence less robust than SCIT for molds | No lasting effect on sensitization | No lasting effect after stopping |
At-Home SCIT (Curex, Alternaria-based)Best
SLIT drops
Avoidance
Medications
Alternaria-based SCIT has the strongest evidence for Pleosporaceae sensitization. Curex now delivers that SCIT as an at-home allergy shot with pricing confirmed in a current program quote: an Alternaria-based serum compounded under USP <797>, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room, a prescribed epinephrine auto-injector confirmed on hand, and allergist-overseen escalation — the most-studied mold immunotherapy without clinic-based shots, evaluated alongside your full Pleosporaceae sensitization profile.
What Stemphylium botryosum SCIT Actually Costs
Curex at-home blood testing identifies Pleosporaceae sensitization patterns including Alternaria (m6) and rAlt a 1 component, helping establish SCIT candidacy without a required office visit first. Most major insurers cover mold SCIT injections under standard allergy benefits when ordered by a board-certified allergist; verify your specific plan's allergy benefit and deductible.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your stemphylium botryosum allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Stemphylium botryosum SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
A positive Stemphylium result almost always signals Pleosporaceae sensitization that overlaps heavily with Alternaria allergy. In clinical practice, Stemphylium is not given as a standalone immunotherapy target — there is no published SCIT randomized controlled trial for Stemphylium botryosum specifically. When your allergist sees this result, they will typically confirm co-sensitization to Alternaria via ImmunoCAP m6 (Alternaria whole extract) and rAlt a 1 component testing. If Pleosporaceae primary sensitization is confirmed, the SCIT pathway uses Alternaria extract with the evidence base from Kuna 2011 and Tabar 2019. The Stemphylium positive is a diagnostic confirmation finding, not a separate treatment decision.
In current US allergy practice, there is no separate Stemphylium botryosum SCIT vial that carries specific clinical trial evidence. No published double-blind placebo-controlled trial has tested Stemphylium as the sole immunizing antigen. When Stemphylium sensitization is confirmed, the standard approach is to administer Alternaria-based SCIT, which targets the shared Pleosporaceae allergen repertoire including the Stem b 4 / Alt a 4 protein that drives cross-reactivity. US extracts for Stemphylium are commercially available but non-standardized. Your board-certified allergist will determine whether Alternaria-anchored mold SCIT is the right approach for your overall sensitization pattern.
Stemphylium botryosum appears on extended mold panels for two reasons: it is a common outdoor saprophyte producing airborne spores that co-occur with Alternaria during the same late-summer season, and its Pleosporaceae family membership makes it a relevant marker of the allergy-risk cluster associated with severe asthma. O'Hollaren 1991 NEJM documented that Pleosporaceae sensitization carries an adjusted OR of 189.5 for respiratory arrest in asthmatics — making any positive result clinically meaningful even without species-specific therapy. The test is informative for risk stratification, not for selecting a uniquely targeted treatment. The result re-routes you to the Alternaria SCIT workup, not away from it.
Stemphylium botryosum and Alternaria alternata are both dematiaceous Pleosporaceae molds sharing similar dark muriform conidia, similar peak-season aerobiology, and similar allergen proteins including the Alt a 4 / Stem b 4 protein disulfide isomerase. The key biological difference is host preference — Stemphylium botryosum is an alfalfa and grass leaf-blight pathogen while Alternaria has broader host range. For SCIT decisions, the difference is minimal: Alternaria carries the RCT evidence (Kuna 2011, Tabar 2019) while Stemphylium does not. Both sensitizations are addressed through Alternaria-based SCIT, which targets the family-level allergen repertoire they share.
No. Co-sensitization to Stemphylium and Alternaria does not require two separate immunotherapy courses. Because the two fungi share the Stem b 4 / Alt a 4 protein and Alt a 1 family-level homologues, a single Alternaria-based SCIT regimen addresses the shared sensitization pathway. Your allergist may include Stemphylium extract in a combined mold vial alongside Alternaria if clinical judgment supports it, but the primary evidence base and dose-titration anchor is Alternaria. Component-resolved testing with rAlt a 1 helps confirm that the positive results represent shared primary sensitization rather than independent sensitization to two separate antigens.
Stemphylium botryosum is primarily an outdoor saprophyte that peaks in late summer and early fall under warm, dry, windy conditions — the same environmental profile as Alternaria. Practical avoidance strategies include monitoring daily outdoor mold spore counts (available from the National Allergy Bureau), keeping windows closed during high-count afternoons, using HEPA air purifiers indoors, avoiding freshly cut grass and agricultural settings during peak season, and showering after extended outdoor exposure. These measures reduce but cannot eliminate exposure, particularly in agricultural regions where alfalfa and cereal crops are abundant. Environmental controls are most useful as an adjunct to pharmacotherapy or SCIT, not as standalone management.
Yes. The Kuna 2011 JACI trial that provides the strongest Alternaria SCIT evidence specifically enrolled children (average age ~9 years) and demonstrated a 63.5% reduction in combined symptom-medication scores at year 3. Children with confirmed Pleosporaceae sensitization and asthma or severe rhinitis are generally considered good SCIT candidates by AAAAI/ACAAI guidelines, particularly because early intervention may modify the long-term course of allergic disease. The decision requires assessment by a board-certified pediatric allergist who will evaluate sensitization tier, asthma control status, and the child's ability to cooperate with injection protocols and the 30-minute observation period.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.